Q3 Earnings Forecast for Humacyte Issued By HC Wainwright

Humacyte, Inc. (NASDAQ:HUMA - Free Report) - Investment analysts at HC Wainwright issued their Q3 2025 earnings per share estimates for Humacyte in a research report issued to clients and investors on Wednesday, May 14th. HC Wainwright analyst S. Ramakanth forecasts that the company will earn ($0.13) per share for the quarter. HC Wainwright has a "Buy" rating and a $4.00 price objective on the stock. The consensus estimate for Humacyte's current full-year earnings is ($1.27) per share. HC Wainwright also issued estimates for Humacyte's Q4 2025 earnings at ($0.12) EPS, FY2025 earnings at ($0.53) EPS, FY2026 earnings at ($0.42) EPS, FY2027 earnings at ($0.23) EPS, FY2028 earnings at $0.13 EPS and FY2029 earnings at $0.39 EPS.

A number of other research firms also recently issued reports on HUMA. Benchmark dropped their price target on Humacyte from $17.00 to $14.00 and set a "buy" rating on the stock in a research report on Wednesday, May 14th. Wall Street Zen upgraded Humacyte from a "sell" rating to a "hold" rating in a research note on Thursday. Finally, D. Boral Capital restated a "buy" rating and set a $25.00 price objective on shares of Humacyte in a research note on Tuesday, May 13th. Two equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $11.71.

Humacyte Price Performance

Shares of HUMA traded up $0.10 during mid-day trading on Monday, reaching $2.44. 2,663,886 shares of the company's stock traded hands, compared to its average volume of 3,747,675. Humacyte has a 12 month low of $1.15 and a 12 month high of $9.97. The stock's 50-day moving average is $1.79 and its two-hundred day moving average is $3.43. The stock has a market cap of $377.71 million, a P/E ratio of -1.81 and a beta of 1.64.

Humacyte (NASDAQ:HUMA - Get Free Report) last issued its quarterly earnings data on Tuesday, May 13th. The company reported ($0.10) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.19) by $0.09. The company had revenue of $0.52 million for the quarter, compared to analysts' expectations of $0.46 million.

Insider Buying and Selling at Humacyte

In other news, CFO Dale A. Sander bought 20,000 shares of the firm's stock in a transaction dated Thursday, April 10th. The shares were acquired at an average price of $1.53 per share, for a total transaction of $30,600.00. Following the completion of the transaction, the chief financial officer now directly owns 40,600 shares in the company, valued at $62,118. The trade was a 97.09% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Kathleen Sebelius acquired 50,000 shares of Humacyte stock in a transaction that occurred on Tuesday, April 8th. The shares were bought at an average price of $1.32 per share, for a total transaction of $66,000.00. Following the transaction, the director now owns 91,207 shares of the company's stock, valued at $120,393.24. This represents a 121.34% increase in their position. The disclosure for this purchase can be found here. Over the last three months, insiders have acquired 83,993 shares of company stock valued at $118,224. Company insiders own 5.10% of the company's stock.

Institutional Investors Weigh In On Humacyte

A number of institutional investors and hedge funds have recently added to or reduced their stakes in HUMA. Integrity Alliance LLC. purchased a new stake in shares of Humacyte in the 1st quarter valued at $112,000. Woodline Partners LP raised its holdings in shares of Humacyte by 38.7% in the 1st quarter. Woodline Partners LP now owns 3,950,000 shares of the company's stock valued at $6,735,000 after buying an additional 1,101,198 shares during the period. Polar Asset Management Partners Inc. purchased a new stake in shares of Humacyte in the 1st quarter valued at $852,000. RA Capital Management L.P. purchased a new stake in shares of Humacyte in the 1st quarter valued at $5,648,000. Finally, Kodai Capital Management LP purchased a new stake in shares of Humacyte in the 1st quarter valued at $124,000. Hedge funds and other institutional investors own 44.71% of the company's stock.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.